There is increasing uncertainty about China approving Synopsys' $35B Ansys acquisition, amid the escalating tariff fight between the US and China
Context & Ripple Effects
The deal had already cleared the EU after the companies offered divestitures, leaving China as a critical outstanding review: the EU's conditional clearance narrowed the transaction's regulatory uncertainty but did not resolve its geopolitical exposure.
The concern became part of a wider approval-and-export-control sequence: China later delayed its review after U.S. restrictions on chip-design software sales, before ultimately approving the transaction. That arc shows how cross-border semiconductor software deals can become contingent on policy shifts outside conventional merger remedies.
First-order effects
- Synopsys and Ansys face a less predictable closing path, with China’s decision becoming a material gating item for their $35B combination.
- The companies must manage merger planning alongside a tariff dispute that is separate from the deal’s competitive merits.
Second-order effects
- A prolonged or uncertain review increases the value of regulatory optionality for chip-design and engineering-software customers, who may defer assumptions about the combined supplier’s product and support roadmap.
- Other U.S. technology vendors seeking Chinese approvals have a fresh signal that commercial transactions can be exposed to changes in bilateral trade policy, not only antitrust analysis.
Third-order effects
- If this pattern persists, merger approvals will function more openly as a point of leverage in the U.S.-China technology relationship, raising execution risk for acquisitions involving strategically important software.
- The practical boundary between export controls, tariffs, and competition review may blur further, encouraging companies to treat market-access dependencies as core deal risks rather than post-signing contingencies.
The trend: Cross-border technology consolidation is increasingly shaped by the interaction of national trade policy, export controls, and merger review.